New 'Bispecific' antibody takes aim at Hard-to-Treat blood cancers

NCT ID NCT02290951

Completed Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a drug called odronextamab in 200 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had stopped responding to prior treatments. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to kill them. The main goals were to check safety and find the right dose, while also looking at whether tumors shrank.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Odronextamab (a bispecific antibody that targets both CD20 on cancer cells and CD3 on immune cells)
What this could lead to: If successful, this could lead to a new treatment option for patients with B-cell cancers who have run out of standard therapies.
What could go wrong: This is an early Phase 1 trial focused on safety, so it is not yet proven to work. Side effects may occur, and the drug may not shrink tumors in most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Assuta Ashdod University Hospital

Ashdod, Southern District, 7747629, Israel
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
CHU Hôpital Lyon Sud

Lyon, 69495, France
Centre Henri Becquerel

Rouen, Haute-Normandie, 76038, France
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)

Boston, Massachusetts, 02215, United States
H. Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Hadassah Medical Center

Jerusalem, Jerusalem, 9112001, Israel
Institut Gustave Roussy

Villejuif, Île-de-France Region, 94800, France
Lady Davis Carmel Medical Center

Haifa, 3436212, Israel
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Meir Medical Center

Kfar Saba, Central District, 44281, Israel
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Rambam Health Care Campus - Hematology and Bone Marrow Transplantation Institute

Haifa, 3109601, Israel
Royal Cornwall Hospitals NHS Trust

Truro, Cornwall, tr1 3lq, United Kingdom
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
Stanford University

Stanford, California, 94305, United States
The Chaim Sheba Medical Center

Tel-Hashomer, Central District, 5265601, Israel
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
Universitatsklinikum Wurzburg

Würzburg, Bavaria, 97080, Germany
University of California, Irvine

Orange, California, 92868, United States
Weill Cornell Medical College

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.